Navidea Biopharmaceuticals Profit Margin

The latest profit margin for NAVB is -81907.54% as of September 2023. That compares with -15065.93% in the prior-year period — down 443.7% year over year. That is below the Healthcare sector average of 13.76%. Investors often review this figure alongside Navidea Biopharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, NAVB's profit margin moved from -15065.93% to -81907.54% — a 443.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Navidea Biopharmaceuticals's valuation or profitability profile.

Against Healthcare companies, NAVB currently prints -81907.54% for profit margin, while the sector average sits near 13.76%. That is roughly 595345.0% below the sector mean. Large gaps often invite a closer look at Navidea Biopharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Navidea Biopharmaceuticals converts resources into returns. At -81907.54%, NAVB may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -15065.93% in the prior-year period — down 443.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting NAVB's profit margin (-81907.54%), review year-over-year change from -15065.93%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.